Kucuk Eyup Veli, Sit Dede, Kayabasi Hasan, Tahra Ahmet, Sobay Resul, Yilmaz Seyma Nur Gunes, Karaoglu Cagla, Ersoy Yesil Ezgi
Department of Urology, University of Health Sciences, Umraniye Training and Research Hospital, Istanbul, Turkey.
Department of Nephrology, University of Health Sciences, Umraniye Training and Research Hospital, Istanbul, Turkey.
North Clin Istanb. 2021 Feb 17;8(2):187-189. doi: 10.14744/nci.2021.70457. eCollection 2021.
SARS-CoV-2 is still a major threat to the world. In this pandemic, transplantation activities have largely been affected worldwide. We are still facing with this pandemic; however, after regulations, we have started our transplantation activities. We report the first kidney transplantation whose recipient and living donor recovered from COVID-19. A 31-year-old male with renal failure was admitted for transplantation with an ABO-compatible relative. The recipient and the donor were tested for COVID-19 before transplantation, and they were both positive with a polymerase chain reaction. The recipient had minor symptoms and received therapy; the living donor also received therapy. Thirty days after recovery, surgery was performed successfully. The recipient was discharged with mycophenolate mofetil (MMF), tacrolimus, and steroid 15 days after surgery. In the follow-up, they were both negative for COVID-19 45 days after surgery. Although there is missing literature regarding safety concerns and short-term follow-up, living-donor transplantation may be considered for patients, who recovered from COVID-19, after careful selection with paying attention to precautions.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）仍然是对世界的重大威胁。在这场大流行中，全球范围内的移植活动受到了很大影响。我们仍面临着这场大流行；然而，在制定相关规定后，我们已开始了移植活动。我们报告了首例受者和活体供者均从新型冠状病毒肺炎（COVID-19）中康复的肾移植病例。一名31岁的肾衰竭男性与一名ABO血型相合的亲属一同入院接受移植手术。移植前对受者和供者进行了COVID-19检测，聚合酶链反应检测结果均为阳性。受者有轻微症状并接受了治疗；活体供者也接受了治疗。康复30天后，成功进行了手术。术后15天，受者服用吗替麦考酚酯（MMF）、他克莫司和类固醇出院。在随访中，术后45天他们的COVID-19检测结果均为阴性。尽管关于安全问题和短期随访的文献较少，但对于从COVID-19中康复的患者，在仔细筛选并注意预防措施后，可考虑进行活体供者移植。
